{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:52:09Z","timestamp":1792637529227,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001203","name":"GlaxoSmithKline Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ijantimicag.2019.06.025","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T12:50:42Z","timestamp":1562158242000},"page":"562-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Off-label use of ceftaroline fosamil: A systematic review"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-2596","authenticated-orcid":false,"given":"Arianna","family":"Pani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Agnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Frantellizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Baratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-2401","authenticated-orcid":false,"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0001","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IPC.0000000000000372","article-title":"Ceftaroline fosamil for treatment of methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia and health care\u2013associated pneumonia","volume":"24","author":"Arshad","year":"2016","journal-title":"Infect Dis Clin Pract"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0002","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/cid\/cir147","article-title":"Ceftaroline: A novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"52","author":"Saravolatz","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0003","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0004","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1038\/s41598-018-26277-9","article-title":"Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility","volume":"8","author":"Yang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0005","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0006","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ijantimicag.2013.07.005","article-title":"Ceftaroline for methicillin-resistant Staphylococcus aureus bacteraemia: Case series and review of the literature","volume":"42","author":"Polenakovik","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0007","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/jmm.0.000566","article-title":"Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus","volume":"66","author":"Azhar","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0008","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkr066","article-title":"Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure","volume":"66","author":"Kelley","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0009","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijid.2017.01.019","article-title":"Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study","volume":"57","author":"Arshad","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ijantimicag.2014.07.024","article-title":"Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations","volume":"44","author":"Paladino","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0011","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob","volume":"61","author":"Zasowski","year":"2017","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0012","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0013","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0014","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0015","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/jac\/dks006","article-title":"Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy","volume":"67","author":"Ho","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0016","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0017","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40265-017-0785-2","article-title":"Early use of ceftaroline fosamil in the United States Veterans Health Care System","volume":"77","author":"Britt","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0018","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clinthera.2016.12.005","article-title":"Combination therapy with vancomycin and ceftaroline for refractory methicillin-resistant Staphylococcus aureus bacteremia: a case series","volume":"39","author":"Gritsenko","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0019","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0020","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dku085","article-title":"Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study","volume":"69","author":"Tattevin","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0021","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0022","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/21548331.2015.1037228","article-title":"Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia","volume":"43","author":"Kaye","year":"2015","journal-title":"Hosp Pract"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1179\/1973947813Y.0000000156","article-title":"Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients","volume":"27","author":"Pasquale","year":"2015","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0024","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0025","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0026","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jgar.2018.01.001","article-title":"DISC: Describing Infections of the Spine treated with Ceftaroline","volume":"13","author":"Watkins","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0027","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijantimicag.2017.05.021","article-title":"Salvage therapy for complex bone and joint infections with ceftaroline: a multicentre, observational study","volume":"50","author":"Malandain","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0028","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0029","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2017.1351729","article-title":"Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus\u202f: a case series","volume":"30","author":"Lalikian","year":"2018","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0030","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/AAC.00285-13","article-title":"Efficacy of ceftaroline fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model","volume":"57","author":"Stucki","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0031","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00286-13","article-title":"Efficacy of ceftaroline fosamil against penicillin-sensitive and -resistant Streptococcus pneumoniae in an experimental rabbit meningitis model","volume":"57","author":"Cottagnoud","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0032","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AAC.04965-14","article-title":"Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37","volume":"59","author":"Sakoulas","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0033","unstructured":"CHMP, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS."},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0034","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0035","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/cit560","article-title":"The empirical combination of vancomycin and a \u03b2-lactam for Staphylococcal bacteremia","volume":"57","author":"McConeghy","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0036","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1128\/AAC.00636-09","article-title":"In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model","volume":"53","author":"Vidaillac","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0037","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1128\/AAC.01386-12","article-title":"Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection","volume":"57","author":"MacGowan","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0038","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diagmicrobio.2014.11.016","article-title":"Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA","volume":"81","author":"Stryjewski","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.06.025_bib0039","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1080\/20009666.2017.1374107","article-title":"Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital","volume":"7","author":"Karki","year":"2017","journal-title":"J Community Hosp Intern Med Perspect"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919301785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:01Z","timestamp":1760376781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919301785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0924857919301785"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.025","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label use of ceftaroline fosamil: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}